[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric-critical-illness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric-critical-illness":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,56,82,106,133,162,189],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100637740","brain-blood-flow-and-cerebral-autoregulation-monitoring-in-critically-ill-children-100637740",false,"NCT07613918","Brain Blood Flow and Cerebral Autoregulation Monitoring in Critically Ill Children","Transcranial Doppler Assessment of Cerebral Autoregulation and Blood Flow Velocity Patterns in Critically Ill Children: A Prospective Observational Study","Inclusion Criteria:\n\n* Has at least one Parent or Legal Guardian who is willing and able to provide informed consent in English\n* Mechanically ventilated (Endotracheal tube)\n* Indwelling arterial catheter\n* Current patient in the American Family Children's Hospital PICU.\n* 1 day to 17.5 years of age\n\nExclusion Criteria:\n\n* Subjects with a known or obvious anatomic barrier preventing safe application of the transcranial Doppler probe (e.g., cranial dressings, cranial fixation hardware, ventricular access devices positioned over insonation sites, or bilateral craniectomies)\n* Patient with known chronic hypertension\n* Admission FSS score \\> 16\n* Tracheostomized patient\n* The designated sub-investigator (Dr. Talal Al Hendawi) and PI (Dr. Neil Munjal) are unavailable to perform the Transcranial Doppler scan at the time of eligibility. All study scans are performed by either Dr. Al Hendawi or Dr.Munjal to ensure standardization and data integrity. Therefore, if they are unavailable (e.g., due to clinical service, leave, or other scheduling constraints), the patient will not be enrolled in the study.\n* Not suitable for study participation due to other reasons at the discretion of the investigators","ALL","1 Day","17 Years",{"count":20,"type":21},125,"ESTIMATED","OBSERVATIONAL","This study uses a non-invasive (external) ultrasound test called Transcranial Doppler (TCD) to measure how blood flows through the major arteries of the brain of children receiving care in the Pediatric Intensive Care Unit (PICU). TCD is already used for clinical reasons in many children, but it is not part of routine monitoring for every critically ill child. By using TCD, the investigators hope to better understand how brain blood flow changes during illness. They will also track children's functional status from before their illness to the time of PICU discharge to explore how brain blood flow patterns relate to neurological outcomes.125 participants will be enrolled and will be on study while in the PICU, estimated to be 3-14 days.",[25,26,27,28,29],"Critical Illness","Pediatric Critical Illness","Respiratory Failure","Traumatic Brain Injury","Cardiac Arrest",[31,32,33,34,35,36,37,38,39,40,41,42],"PICU","infant","Transcranial Doppler Assessment","Cerebral Autoregulation","Blood Flow Velocity","children","mechanical ventilation","neurocritical care","pulsatility index","Mean flow index","neonate","pediatric critical care","NOT_YET_RECRUITING","2026-06-02",{"date":46,"type":47},"2026-06-04","ACTUAL",{"date":49,"type":21},"2026-06",{"date":51,"type":21},"2028-05",{"name":53,"class":54},"University of Wisconsin, Madison","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100622988","building-relationship-improving-dialogue-and-growing-empathy-bridge-an-intervention-to-support-decision-making-for-critically-ill-children-100622988","NCT07390773","Building Relationship, Improving Dialogue, and Growing Empathy (BRIDGE): An Intervention to Support Decision Making for Critically Ill Children","BRIDGE","Inclusion Criteria:\n\nChild inclusion criteria will include:\n\n* Age \\\u003C 5 years\n* Admission to a critical care unit within the preceding 14 days\n* An anticipated serious health care decision, defined as a decision about initiating, not initiating, or withdrawing life-sustaining treatment and\u002For a decision about major intervention.\n\nParent inclusion criteria will include:\n\n* Age ≥ 18 years\n* The ability speak English or Spanish.\n\nClinician inclusion criteria will include\n\n* Clinical team member of an enrolled child and parent in the intervention group\n* Completion of residency or equivalent training.\n\nExclusion Criteria:\n\n* Children, parents or clinicians who do not meet the inclusion criteria above.",{"count":64,"type":21},495,"INTERVENTIONAL",[67],"NA","Parents of young children in the intensive care unit may be faced with decisions about their child's care. The Building Relationship, Improving Dialogue, and Growing Empathy (BRIDGE) intervention was designed to help support parents as they make decisions for their child and communicate with the health care team. The main questions this study aims to answer are:\n\n1. Do parents who receive the BRIDGE intervention report being better prepared to make decisions for their child?\n2. Do parents who receive the BRIDGE intervention report less regret about the decisions they made for their child?\n\nParticipants will complete surveys at baseline and approximately 2 weeks, 6 months, and 12 months following enrollment. Some participants will also participate in interviews about their experiences.",[70,71,26],"Decision Making","Neonatal Critical Illness","2026-05-21",{"date":74,"type":47},"2026-05-22",{"date":76,"type":21},"2026-07",{"date":78,"type":21},"2028-10",{"name":80,"class":54},"Duke University",3,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":18,"enrollmentInfo":90,"targetDuration":4,"studyType":65,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":55},"100622512","feasibility-of-light-therapy-in-the-pediatric-intensive-care-unit-icu-100622512","NCT07384585","Feasibility of Light Therapy in the Pediatric Intensive Care Unit (ICU)","Feasibility of Light Therapy in the Pediatric ICU","Inclusion Criteria:\n\n* Anticipated to remain admitted to the study hospital pediatric ICU for additional 48 hours\n* English-speaking parent\u002Flegally authorized representative available at the bedside\n\nExclusion Criteria:\n\n* Patients unable to open their eyes to receive light therapy (Glasgow Coma Scale eye opening score of 1 or neuromuscular blockade)\n* Patients with contraindications to light therapy (e.g., migraines, retinal disease, diseases associated with retinal complications, blindness, bipolar disorder, seizure disorder, traumatic brain injury)\n* Suspected\u002Fidentified neglect\u002Fabuse, Child Protective Services involvement, or ward of state\n* Children receiving palliative\u002Fend-of-life care\n* Unable to fit light box\u002Fcart in patient room","4 Years",{"count":91,"type":21},30,[67],"The goal of this clinical trial is to understand how easy or difficult it is for critically ill children (4-17 years old) to have light therapy while in the pediatric ICU. Participants will have a light meter at their bedside to measure light levels. Each morning, a light box will be placed at their bedside. Children, family, and staff will be asked to completed feedback surveys regarding the light therapy. Study participation will continue for a maximum of 5 days.",[95,96,26],"Circadian Dysregulation","Light Exposure","RECRUITING","2026-05-20",{"date":74,"type":47},{"date":101,"type":47},"2026-03-26",{"date":103,"type":21},"2027-01",{"name":105,"class":54},"Laura Beth Kalvas",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":55},"100629723","transcutaneous-po-monitoring-in-picu-100629723","NCT07478380","Transcutaneous pO₂ Monitoring in PICU","COMPARISON OF TRANSCUTANEOUS PCO₂ AND PO₂ MEASUREMENTS WITH ARTERIAL BLOOD GAS ANALYSIS IN PEDIATRIC INTENSIVE CARE PATIENTS: IS TRANSCUTANEOUS pO₂ A RELIABLE ALTERNATIVE?","Eligibility Criteria\n\nInclusion Criteria:\n\n* Age between 1 month and 18 years\n* Admission to the Pediatric Intensive Care Unit (PICU)\n* Presence of an arterial catheter allowing arterial blood gas (ABG) sampling\n* Simultaneous or paired transcutaneous pCO₂ and pO₂ monitoring available\n* Hemodynamically stable at the time of measurement\n\nExclusion Criteria:\n\n* Severe skin disease, burns, or local skin infection at the transcutaneous sensor site\n* Severe peripheral perfusion impairment (e.g., refractory shock or high-dose vasopressor support)\n* Congenital or acquired conditions interfering with accurate transcutaneous measurements\n* Technical failure or inability to obtain reliable transcutaneous readings\n* Missing or incomplete paired ABG-transcutaneous measurement data","1 Month","18 Years",{"count":116,"type":21},50,"Arterial blood gas analysis is commonly used in pediatric intensive care units (PICUs) to assess oxygen and carbon dioxide levels in critically ill children. However, arterial blood sampling is invasive, can be painful, and may need to be repeated frequently. Transcutaneous monitoring provides a noninvasive method to continuously measure oxygen (pO₂) and carbon dioxide (pCO₂) levels through the skin, but its accuracy in critically ill pediatric patients requires further evaluation.\n\nThe purpose of this observational study is to compare transcutaneous pO₂ and pCO₂ measurements with arterial blood gas values in pediatric intensive care unit patients. By analyzing paired measurements obtained simultaneously during routine clinical care, this study aims to evaluate the agreement between transcutaneous and arterial measurements, with a particular focus on whether transcutaneous pO₂ can serve as a reliable alternative to arterial sampling.\n\nThe results of this study may help clarify the role of transcutaneous monitoring in pediatric intensive care and may contribute to reducing the need for invasive blood sampling in selected patients.",[26],[120,121,122,123],"Pediatric Intensive Care Unit","Transcutaneous Monitoring","Arterial Blood Gas","Noninvasive Monitoring","2026-03-13",{"date":126,"type":47},"2026-03-17",{"date":128,"type":47},"2026-03-10",{"date":130,"type":21},"2026-10-10",{"name":132,"class":54},"Istanbul Medeniyet University",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":55},"100628528","indirect-calorimetry-measurement-in-the-pediatric-intensive-care-units-smallest-patients-100628528","NCT07462806","Indirect Calorimetry Measurement in the Pediatric Intensive Care Unit's Smallest Patients","Indirect Calorimetry Measurement in the Paediatric Intensive Care Unit's Smallest Patients","Q-NRG2025","Inclusion Criteria: Newborns and infants admitted to the PICU with body weight from 0,5 up to 10 kilograms. Either requiring mechanically ventilation, with FiO2 \\\u003C 70%, PIP\\\u003C30 cmH2O and no leakage in the ventilation system. Or spontaneous breathing patients tolerating measurements with canopy.\n\nExclusion Criteria:\n\nIn mechanically ventilated patients' unstable ventilation including ventilation settings changed during the last 60 minutes (FiO2 \\>70%, PIP\\>30 cmH2O, or ventilation system leakage). Patients spontaneous breathing not tolerating measurements with canopy.",{"count":142,"type":21},80,"Indirect calorimetry is considered the reference method for measuring energy expenditure in intensive care patients. However, in infants and small children weighing less than 10 kilograms, its clinical use has historically been limited due to technical challenges related to low tidal volumes, potential increases in dead space, and measurement precision.\n\nThe goal of this observational study is to evaluate the feasibility and performance of indirect calorimetry using the Q-NRG+ device in critically ill children weighing less than 10 kg who are admitted to a pediatric intensive care unit.",[26],[26,146,147,148,149,150,151,152,153],"weight under 10 kilogram","Indirect calorimetry","Energy expenditure","Nutritional assessment","Q-NRG+","Pediatric intensive care","chofield equation","Metabolic monitoring","2026-03-05",{"date":128,"type":47},{"date":157,"type":21},"2026-04",{"date":159,"type":21},"2027-12",{"name":161,"class":54},"Karolinska Institutet",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":65,"phases":173,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":4},"100622812","interactive-digital-art-based-relaxation-program-100622812","NCT07388485","Interactive Digital Art-Based Relaxation Program","The Effect of an Interactive Digital Art-Based Relaxation Program on Physiological Parameters, Anxiety, and Emotional Distress in Children Receiving Treatment in the Pediatric Intensive Care Unit: A Randomized Controlled Trial","Inclusion Criteria:\n\n* • Be between 7 and 12 years of age\n\n  * Be conscious and able to respond to commands\n  * Not be receiving sedative\u002Fanalgesic infusion or be at minimal sedation level (RASS ≥ -1)\n  * Have been monitored in intensive care for at least 24 hours\n  * Have stable vital signs\n  * Have no visual or auditory perception loss\n  * Parental consent and verbal consent from the child must have been obtained\n\nExclusion Criteria:\n\n* Severe neurological deficit or motor impairment\n\n  * Severe pain, delirium, or agitation\n  * Severe psychiatric diagnosis or requirement for high-dose sedation\n  * Being in the terminal phase","7 Years","12 Years",{"count":172,"type":21},60,[67],"This randomized controlled trial aims to evaluate the effects of an Interactive Digital Art-Based Relaxation Program on physiological parameters, anxiety levels, and emotional distress in children aged 7-12 years receiving care in a pediatric intensive care unit (PICU). Children in the intervention group will receive three short, nurse-guided digital art-based relaxation sessions delivered via tablet, while the control group will receive standard PICU nursing care. Outcomes will be assessed using physiological measurements and validated psychological assessment tools before and after the intervention.",[26,176],"Anxiety",[120,178,179],"Children","Interactive Digital Art-Based Relaxation","2026-01-31",{"date":182,"type":47},"2026-02-05",{"date":184,"type":21},"2026-01-20",{"date":186,"type":21},"2027-03-20",{"name":188,"class":54},"Gazi University",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":197,"maxAge":114,"enrollmentInfo":198,"targetDuration":4,"studyType":65,"phases":200,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":55},"100595673","phase-4-randomized-control-study-in-resuscitation-of-sepsis-trial-100595673","NCT07035509","Randomized Control Study in REsuscitation of SEpsis Trial","Randomized Control Study on Normal Saline vs Plasmalite vs Plasma in REsuscitation of SEpsis Trial (RESET) - A Feasibility and Comparative Study","RESET","Inclusion criteria\n\n* Age: ≥1 month (corrected gestational age) to 18 years.\n* Diagnosis of sepsis with at least one of the following conditions:\n* Signs of poor perfusion: prolonged capillary refill ≥2 sec, weak peripheral pulses, unexplained metabolic acidosis (base deficit \\> (-)5.0 mEq\u002FL), altered. mental status, lactate ≥2 mmol\u002FL (sample drawn without tourniquet use. (Appendix 2). OR\n* Systolic blood pressure (SBP) below the 5th percentile for age.\n* Signed informed consent from the patient's legal guardian.\n\nExclusion Criteria:\n\n* Receipt of ≥2 boluses of NS 0.9% or balanced solution in the last 24 hours for the current sepsis episode (bolus defined as ≥10 mL\u002Fkg (max. 500 mL) of NS\u002FRL given in \\\u003C30 min).\n* Known allergic reaction to plasma-derived products.\n* Known IgA deficiency.\n* Suspected or confirmed congestive heart failure.\n* Nephrotic syndrome.\n* Known chronic kidney disease with fluid overload or congestive heart failure.\n* Diagnosed hemorrhagic dengue fever confirmed by antigen or serology (NS1 or IgM positive).","4 Weeks",{"count":199,"type":21},150,[201],"PHASE4","Crystalloids vs. Synthetic Plasma for Fluid Resuscitation in Children with Sepsis - REsuscitation of SEpsis Trial (RESET): A Comparative and Feasibility Study This research study, called the REsuscitation of SEpsis Trial (RESET), is a randomized clinical trial comparing crystalloids and synthetic plasma for fluid resuscitation in children with sepsis. Below, we explain some key aspects you should be aware of.\n\nWhat is a Clinical Trial? A clinical trial is a type of medical research designed to gather more information on how our bodies respond to medications or other treatments.\n\nMost new medical treatments must be evaluated in clinical trials before they can be approved by government agencies. These agencies ensure that new treatments are not only safe but also beneficial for patients-what medicine refers to as being \"safe and effective.\" If a new treatment has not yet been approved, it is considered \"experimental.\"\n\nResearchers analyze the results of multiple clinical trials to determine which medications work best and how they function. The advancement of medical science requires the participation of many people in numerous studies worldwide.\n\nWhat is the Purpose of This Study? This study evaluates whether Octaplas LG helps children and adolescents with sepsis and whether it improves the function of blood vessels inflamed due to infection. Sepsis occurs when an infection severely affects a person's health.\n\nOctaplas LG is a medication approved for use in Colombia. It is known as pharmaceutical plasma and is obtained from voluntary donors worldwide. It undergoes an ultra-detailed sterilization process using the most advanced techniques for processing blood derivatives. In medicine, fresh frozen plasma (FFP) is typically used, which is the equivalent of Octaplas LG but with far fewer industrial sterilization processes. These additional processes in Octaplas LG significantly reduce the risk of transmitting infections.\n\nAlthough Octaplas LG is approved by INVIMA, its use for fluid resuscitation has not yet been approved.\n\nThis study will compare Octaplas LG with normal saline solution and Ringer's lactate, which are commonly used for rehydrating patients. All three treatments will be administered in the same manner.\n\nWhy is My Child Being Asked to Participate?\n\nYour child is being invited to participate in this clinical study because:\n\nThey are receiving care in the pediatric intensive care unit (PICU). They are between one month and 18 years old. They have been diagnosed with sepsis and require fluid resuscitation. Your child's participation is voluntary. If you decide not to participate, your child will not lose any medical benefits. Your child's doctor has determined that they may be a good candidate for this study. You are free to discuss participation with your family, friends, or another physician.\n\nSome members of your child's healthcare team may also be involved in this research. They are dedicated to your child's care as well as the objectives of this study. However, you are not obligated to participate. If you choose to enroll your child, you will be asked to sign an informed consent form.\n\nHow Will My Child Be Assigned to a Treatment Group? Upon admission to the pediatric intensive care unit (PICU), if your child has a confirmed sepsis diagnosis and requires intravenous fluids or plasma to support heart function, they will be randomly assigned to one of the three treatment groups.\n\nRandomization is a research method used in clinical trials to assign patients to study groups in an unbiased way-similar to drawing numbers from a hat. Neither you, your child's doctor, nor the researchers will choose which group your child is placed in. Instead, a computer will randomly assign them to a group.\n\nTreatment Groups:\n\nGroup 1: Normal Saline (0.9% Sodium Chloride)\n\nYour child will receive the standard treatment for sepsis, including antibiotics, intravenous fluids, heart function monitoring, mechanical ventilation if needed, and blood pressure medications (vasopressors) if necessary.\n\nGroup 2: Ringer's Lactate\n\nIn addition to standard sepsis management, your child will receive Ringer's lactate, another commonly used resuscitation fluid in pediatric sepsis.\n\nGroup 3: Octaplas LG\n\nIn addition to standard sepsis management, your child will receive pharmaceutical synthetic plasma, which contains proteins and essential blood components that have undergone advanced processing to eliminate the risk of infectious disease transmission.\n\nHow Many Children Will Participate in This Study? At Fundación Cardioinfantil-Instituto de Cardiología, we are seeking the participation of approximately 150 children in this study.\n\nHow Long Will My Child Be in the Study? Your child will remain in their assigned treatment group for up to 28 days from PICU admission or until they no longer require intensive care hospitalization.",[204,26],"Septic Shock",[206,207,208,209,210,211],"sepsis","Septic shock","Fluid bolus","plasma","pediatric","crystalloids","2025-06-16",{"date":214,"type":47},"2025-06-25",{"date":216,"type":21},"2025-07-01",{"date":218,"type":21},"2026-07-15",{"name":220,"class":54},"Fundación Cardioinfantil Instituto de Cardiología"]